e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Experimental pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry
L. J. Hwang, J. Teeter, M. Louie, H. Toft Sørensen, C. de Luise (New York, United States Of America; Aarhus, Denmark)
Source:
Annual Congress 2011 - Experimental pulmonary hypertension
Session:
Experimental pulmonary hypertension
Session type:
Poster Discussion
Number:
3339
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. J. Hwang, J. Teeter, M. Louie, H. Toft Sørensen, C. de Luise (New York, United States Of America; Aarhus, Denmark). Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry. Eur Respir J 2011; 38: Suppl. 55, 3339
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS)
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan
Source: Eur Respir J 2005; 26: Suppl. 49, 563s
Year: 2005
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Population pharmacokinetic (PK) of sildenafil in paediatric and adult pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Risk stratification in pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – New trends in the management of pulmonary hypertension
Year: 2018
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Risk stratification in patients with pulmonary arterial hypertension (PAH) and candidates for lung or heart-lung transplantation
Source: Virtual Congress 2021 – All about pulmonary arterial hypertension
Year: 2021
Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Survival in pulmonary hypertension in Spain: insights from the Spanish registry},
Source: Eur Respir J 2012; 40: 596-603
Year: 2012
Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients
Source: Annual Congress 2007 - Pulmonary hypertension in the clinic
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept